Secondary analysis of the LACI-2 phase 2b factorial trial (363 adults with lacunar stroke): at 6 months, isosorbide mononitrate vs control was linked to fewer composite stroke, MI, dependency, cognitive impairment or death events (adjusted OR 0.74, 95% CI 0.55–0.99).
Secondary analysisn = 363
Bath et al. Isosorbide Mononitrate/Cilostazol for Lacunar Cerebral Small Vessel Disease-Outcomes at 6 Months in the LACI-2 Randomized Controlled Trial